Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research (Q40590489)

21 September 2017

title

Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research (English)

1 reference

21 September 2017

1 reference

Laura E Targownik

1

1 reference

21 September 2017

Samy Suissa

series ordinal

2

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2015

1 reference

The American Journal of Gastroenterology

21 September 2017

published in

1 reference

21 September 2017

volume

110

1 reference

21 September 2017

issue

12

1 reference

21 September 2017

page(s)

1647-1650

1 reference

The limitations of randomized controlled trials in predicting effectiveness

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Limitations of the randomized controlled trial in evaluating population-based health interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Randomized, controlled trials, observational studies, and the hierarchy of research designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Pharmacoepidemiology in practice. Current status and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Immortal time bias in pharmaco-epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Immortal time bias and infliximab-related mortality and malignancy incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

Time-dependent covariates in the Cox proportional-hazards regression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

21 January 2018

Response to Targownik

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.210

The importance of accounting for immortal time bias in pharmacoepidemiologic analyses.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26323186

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Exclusion of immortal person-time

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26323186

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/AJG.2015.210

1 reference

Dimensions Publication ID

21 September 2017

1006248215

0 references

1 reference